Autonomic drugs in ophthalmology: some problems and promises. Section II: Anticholinergic drugs.
D001285:Atropine / Q000494:pharmacology / Q000627:therapeutic use; D001337:Autonomic Agents / Q000627:therapeutic use*; D002648:Child; D003517:Cyclopentanes / Q000494:pharmacology; D004123:Dimethylamines / Q000494:pharmacology; D004342:Drug Hypersensitivity / Q000209:etiology; D005128:Eye Diseases / Q000188:drug therapy*; D005901:Glaucoma / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007429:Intraocular Pressure / Q000187:drug effects; D008297:Male; D008916:Miotics / Q000627:therapeutic use; D009184:Mydriatics / Q000009:adverse effects / Q000627:therapeutic use; D010276:Parasympatholytics / Q000627:therapeutic use; D010648:Phenylacetates / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D011413:Propantheline / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology
D001337:Autonomic Agents; D003517:Cyclopentanes; D004123:Dimethylamines; D008916:Miotics; D009184:Mydriatics; D010276:Parasympatholytics; D010648:Phenylacetates; D011725:Pyridines; D010862:Pilocarpine; D011413:Propantheline; D001285:Atropine